Kodiak Sciences (KOD) Price & Analysis

Compare

409 Followers

KOD Stock Chart & Stats

$21.94

-$0.42(-4.39%)

At close: Jan 08 4:00 PM EST

$21.94

-$0.42(-4.39%)

Day’s Range― - ―

52-Week Range$1.92 - $23.63

Previous CloseN/A

Volume87.32K

Average Volume (3M)834.20K

Market Cap

$1.16B

Enterprise Value$955.47M

Total Cash (Recent Filing)$72.04M

Total Debt (Recent Filing)$62.20M

Price to Earnings (P/E)―

Beta2.72

Next Earnings

Mar 26, 2026

EPS Estimate

-1.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.16

Shares Outstanding53,048,428

10 Day Avg. Volume749,025

30 Day Avg. Volume834,196

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)3.48

Price to Sales (P/S)0.00

P/FCF Ratio-4.44

Enterprise Value/Market Cap0.82

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-36.07

Enterprise Value/Ebitda-5.01

Forecast

1Y Price Target

$24.17

Price Target Upside10.16% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)-3.99

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst RatingAnalyst reiterates a Buy rating and has raised the price target from $24 to $26 per share.

Clinical TrialsThe Phase 3 GLOW1 trial in diabetic retinopathy showed durability and 6-month dosing benefits.

Mechanism Of ActionThe absence of inflammation/macular edema rebound off-treatment bodes well for the IL-6/VEGF mechanism to provide lasting disease remission.

Bears Say

Cash Burn RateKodiak Sciences has an annualized cash burn of $230 million, with only 0.5 years of cash left.

Financial HealthYears of cash left for the company is limited to 0.5 years.

Market OpportunityKOD's tarcocimab is in GLOW2 ph.III for DR with data expected, but there is an expectation of limited market opportunity due to low VEGF use in NPDR patients without DME.

Kodiak Sciences News

Kodiak Sciences price target raised to $26 from $24 at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Kodiak Sciences (KOD) to $26 from $24...

16d ago

KOD

Kodiak Sciences reports Q3 EPS ($1.16), consensus ($1.04)

“Kodiak Sciences (KOD) has entered a period of strong, sustained momentum driven by compelling clinical data, accelerated execution...

20d ago

KOD

Kodiak Sciences upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield upgraded Kodiak Sciences (KOD) to Buy from Neutral with a price target of...

22d ago

KOD

Kodiak Sciences reports data from study of KSI-101 in patients with MESI

Kodiak Sciences (KOD) announced follow-up data from the APEX study of KSI-101 in patients with MESI. MESI is...

28d ago

KOD

Kodiak Sciences’ Promising Outlook: Buy Rating Affirmed Amid Positive Drug Developments and Strategic Adjustments

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Kodiak Sciences today and set a price target...

16d ago

KOD

Kodiak Sciences: Promising Pipeline and Strategic Differentiation Drive Buy Rating

Kodiak Sciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Dolezal from...

19d ago

KOD

Kodiak Sciences Faces Financial Challenges Amid R&D Focus

Kodiak Sciences ( ($KOD) ) has released its Q3 earnings. Here is a breakdown of the information Kodiak...

20d ago

KOD

Is KOD a Buy, Before Earnings?

Kodiak Sciences (KOD) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street analysts...

23d ago

KOD

Kodiak Sciences’ KSI-101: Promising Phase 1b Results and Competitive Edge Justify Buy Rating

Patrick Dolezal, an analyst from LifeSci Capital, maintained the Buy rating on Kodiak Sciences. The associated price target...

28d ago

KOD

Kodiak Sciences’ Phase 3 Trial: A Potential Game-Changer for Macular Edema Treatment

Kodiak Sciences (($KOD)) announced an update on their ongoing clinical study. Study Overview: Kodiak Sciences is conducting a...

1M ago

KOD

Kodiak Sciences’ Phase 3 Study on KSI-101: A Potential Game-Changer for Macular Edema

Kodiak Sciences (($KOD)) announced an update on their ongoing clinical study. Study Overview: Kodiak Sciences is conducting a...

1M ago

KOD

Kodiak Sciences upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded Kodiak Sciences (KOD) to Overweight from Neutral with a price target of $24, up from $15....

1M ago

KOD

JPMorgan healthcare analysts hold an analyst/industry conference call

Healthcare Analysts discuss the recently held ESMO 2025 (European Society for Medical Oncology) with Kodiak Sciences (KOD) on...

1M ago

KOD

Kodiak Sciences initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Kodiak Sciences (KOD) with an Outperform rating and $40 price target Published first...

1M ago

KOD

KOD FAQ

What was Kodiak Sciences Inc’s price range in the past 12 months?

Kodiak Sciences Inc lowest stock price was $1.92 and its highest was $23.63 in the past 12 months.

What is Kodiak Sciences Inc’s market cap?

Kodiak Sciences Inc’s market cap is $1.16B.

When is Kodiak Sciences Inc’s upcoming earnings report date?

Kodiak Sciences Inc’s upcoming earnings report date is Mar 26, 2026 which is in 113 days.

How were Kodiak Sciences Inc’s earnings last quarter?

Kodiak Sciences Inc released its earnings results on Nov 13, 2025. The company reported -$1.16 earnings per share for the quarter, missing the consensus estimate of -$1.037 by -$0.123.

Is Kodiak Sciences Inc overvalued?

According to Wall Street analysts Kodiak Sciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kodiak Sciences Inc pay dividends?

Kodiak Sciences Inc does not currently pay dividends.

What is Kodiak Sciences Inc’s EPS estimate?

Kodiak Sciences Inc’s EPS estimate is -1.03.

How many shares outstanding does Kodiak Sciences Inc have?

Kodiak Sciences Inc has 53,048,428 shares outstanding.

What happened to Kodiak Sciences Inc’s price movement after its last earnings report?

Kodiak Sciences Inc reported an EPS of -$1.16 in its last earnings report, missing expectations of -$1.037. Following the earnings report the stock price went up 3.392%.

Which hedge fund is a major shareholder of Kodiak Sciences Inc?

Currently, no hedge funds are holding shares in KOD

Kodiak Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-207.92%

Trailing 12-Months

Asset Growth

-41.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kodiak Sciences Inc

Kodiak Sciences Inc. (KOD) is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of retinal diseases. The company is headquartered in Palo Alto, California, and operates within the biotechnology and pharmaceutical sectors. Its core product candidate is KSI-301, an investigational therapy designed to improve outcomes for patients with retinal vascular diseases such as wet age-related macular degeneration and diabetic eye diseases.

Kodiak Sciences (KOD) Earnings & Revenues

Historic Earnings Reports

KOD Stock 12 Month Forecast

Average Price Target

$24.17

▲(10.16% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","11":"$11","21":"$21","31":"$31","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,11,21,31,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.12,19.803076923076922,21.486153846153847,23.16923076923077,24.852307692307694,26.535384615384615,28.21846153846154,29.90153846153846,31.584615384615383,33.26769230769231,34.950769230769225,36.63384615384615,38.316923076923075,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.12,18.585384615384616,19.05076923076923,19.51615384615385,19.981538461538463,20.446923076923078,20.912307692307692,21.37769230769231,21.843076923076925,22.30846153846154,22.773846153846154,23.239230769230772,23.704615384615387,{"y":24.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.12,17.803076923076922,17.486153846153847,17.16923076923077,16.852307692307694,16.535384615384615,16.21846153846154,15.901538461538461,15.584615384615386,15.267692307692307,14.950769230769232,14.633846153846154,14.316923076923077,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.89,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.95,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.49,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":15.76,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.12,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >